Topiramate Capsule, Extended Release
Product Images NDC 27808-325

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 27808-325). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cranbury Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ink (Topiramate Extended Release Capsules 1)

Topiramate extended-release oral capsules in a blister pack. The capsules are yellow and white, with printed text visible on the capsules indicating dosing or identifying marks. The blister pack holds multiple capsules arranged in rows.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 10)

Topiramate extended release capsules packaging by Cranbury Pharmaceuticals, LLC. The label lists multiple available strengths including 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg per capsule, intended for oral use. The label features standard pharmaceutical information and branding in a rectangular blister pack format.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 11)

Topiramate extended release oral capsules in a clear blister pack, showing five capsules each in separate compartments. The capsules are oblong and two-toned in color, with one half pink and the other half white. The packaging does not have visible text or branding.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 12)

Topiramate extended release capsules packaging label showing 100 mg strength. The label includes the proprietary name Topiramate, the labeler Cranbury Pharmaceuticals, LLC, and dosage form as oral capsules. The image depicts a carton and a white bottle with a white cap.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 13)

Topiramate extended-release capsules in a clear blister pack. Capsules have two colors, one white and one beige or light brown, with printed alphanumeric codes on each side. The pack contains multiple capsules arranged in rows, suitable for oral administration. Labeler is Cranbury Pharmaceuticals, LLC.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 14)

Topiramate extended-release capsules in assorted strengths (100 mg, 150 mg, 200 mg, 25 mg, 50 mg) shown in seven blister strips of ten capsules each. The capsules are color-coded and printed with their strength, arranged in a packaging layout. The labeler is Cranbury Pharmaceuticals, LLC.*

FDA Label Image

Topiramte25mg30ct (Topiramate Extended Release Capsules 15)

Topiramate Extended-Release Capsules, USP 25 mg oral, once-daily dosing, packaged in a 30-capsule bottle. The label includes storage instructions to keep at 20° to 25°C and protect from moisture. Manufactured by Yichang Humanwell Oral Solid Dosage Plant in China and labeled by Cranbury Pharmaceuticals, LLC.*

FDA Label Image

Topiramate50mg30ct (Topiramate Extended Release Capsules 16)

Label for Topiramate Extended-Release Capsules, USP 50 mg, an oral extended-release capsule for once-daily dosing. The package contains 30 capsules and is manufactured by Cranbury Pharmaceuticals, LLC. The label includes dosing information, storage instructions, and a child-resistant packaging notice.*

FDA Label Image

Topiramate100mg30ct (Topiramate Extended Release Capsules 17)

Label for Topiramate Extended-Release Capsules, USP 100 mg by Cranbury Pharmaceuticals, LLC. The label states once-daily dosing with 30 capsules per container. It includes storage instructions, manufacturer details including Yichang Humanwell in China, and a barcode. The label also advises dispensing the medication guide to each patient.*

FDA Label Image

Topiramate150mg30ct (Topiramate Extended Release Capsules 18)

Label for Topiramate Extended-Release Capsules, USP 150 mg by Cranbury Pharmaceuticals, LLC. The label shows the NDC number 27808-328-01 and indicates the product is for once-daily dosing. The package contains 30 capsules. Storage instructions and manufacturer details in Yichang, China, and Cranbury Pharmaceuticals in New Jersey, USA, are included.*

FDA Label Image

Topiramate200mg30ct (Topiramate Extended Release Capsules 19)

Label for Topiramate Extended-Release Capsules, USP 200 mg by Cranbury Pharmaceuticals, LLC. The package contains 30 capsules with once-daily dosing. The label includes storage instructions, a pharmacist dispensing note directing to the online Medication Guide, and manufacturer details including Yichang Humanwell Oral Solid Dosage Plant in China. It notes the product is child-resistant and provides USP storage temperature guidelines.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 2)

Topiramate extended-release capsules are displayed on a white background. The capsules are bicolored, featuring a half white and half blue design, each marked with identifiers in black text. This image shows multiple capsules, illustrating the oral dosage form manufactured by Cranbury Pharmaceuticals, LLC.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 3)

Topiramate extended release capsules packaging. The front label shows the product name Topiramate, the dosage form as extended release capsules, and the labeler Cranbury Pharmaceuticals, LLC. The label includes multiple strengths ranging from 25 mg to 200 mg per capsule. The design includes a white box with blue and black text and a blue and green graphic element.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 4)

Topiramate extended-release capsules packaging from Cranbury Pharmaceuticals, LLC. The bottle label displays the proprietary name Topiramate with an extended-release capsule designation. The visible strength on the bottle is 100 mg. The container is a white plastic bottle with a white child-resistant cap, and the label includes black and green text on a white background.*

FDA Label Image

Ink (Topiramate Extended Release Capsules 5)

Topiramate 25 mg extended-release oral capsules in a blister pack. The carton displays the product name Topiramate, strength 25 mg, dosage form extended-release capsules, and the labeler Cranbury Pharmaceuticals, LLC. The blister contains 30 capsules with a blue and white color scheme.*

FDA Label Image

Structure (Topiramate Extended Release Capsules 6)

Chemical structure diagram of the active ingredient Topiramate, showing its molecular configuration with functional groups including oxo, sulfonamide, and methyl substituents.*

FDA Label Image

Figure-1 (Topiramate Extended Release Capsules 7)

A line chart showing cumulative rates for time to first seizure comparing Topiramate 50 mg/day and Topiramate 400 mg/day over 500 days. The graph plots cumulative seizure rates on the vertical axis and time in days on the horizontal axis, with two distinct lines representing each dose group. A p-value of 0.0002 is displayed, indicating statistical comparison between groups.*

FDA Label Image

Figure-2 (Topiramate Extended Release Capsules 8)

A bar chart comparing the proportion of patients by percentage reduction in seizure frequency from baseline. It displays data for two groups: Placebo and Topiramate Extended-Release Capsules 200 mg/day, across five reduction categories: Worse, 0 to <25%, 25 to <50%, 50 to <75%, and 75 to 100%.*

FDA Label Image

Figure-3 (Topiramate Extended Release Capsules 9)

A bar chart comparing changes from baseline to double-blind phase in average monthly migraine period rate across four groups: Placebo, Topiramate 50 mg/day, 100 mg/day, and 200 mg/day. Data shown for two studies (Study 11 and Study 12) with error bars, indicating statistical significance at p<0.010 and p<0.001 for some Topiramate doses versus placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.